Compare LRN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | CRNX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 2007 | 2018 |
| Metric | LRN | CRNX |
|---|---|---|
| Price | $85.15 | $33.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $106.75 | $74.78 |
| AVG Volume (30 Days) | 685.6K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.87 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $917,734,000.00 | $1,039,000.00 |
| Revenue This Year | $6.18 | $722.66 |
| Revenue Next Year | $4.74 | $183.79 |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $24.10 |
| 52 Week High | $171.17 | $57.99 |
| Indicator | LRN | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 29.20 |
| Support Level | $80.62 | $33.23 |
| Resistance Level | $89.29 | $37.23 |
| Average True Range (ATR) | 2.69 | 1.62 |
| MACD | -0.14 | 0.13 |
| Stochastic Oscillator | 48.57 | 8.33 |
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.